3 results
Primary objective: To evaluate the expected increase of the Microvascular Flow Index perioperative using a SDF-imaging device and the systemic inflammatory response by measuring inflammation biomarkers.Secondary objective: To learn more about the…
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
The purpose of this study is to see if Crinecerfont is effective in reducing daily glucocorticoid dosage while maintaining adrenal androgen control.The purpose of the study is also to see if Crinecerfont is effective in reducing adrenal steroid…